
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Washington, D.C. - A unique case report of necrobiosis lipoidica (NL) within coronary artery bypass graft scars presents the dermatologist with the ongoing challenge of managing an ever-present skin disorder that denies therapy, according to Shannon Heck, M.D.






